Yes
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52
|
Neoplastic Lesions
|
Yes
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/51 0/53 1/51 3/55 1/59
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 3/50 2/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/52 0/50 1/51 2/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 25/50 45/51 46/53 45/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/51 2/53 4/51 3/53 3/59
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Seminal Vesicle
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/52 1/50 4/51 11/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Unspecified)
|
Clear Evidence |
Equivocal Evidence |
HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 3/50 OR ADENOCARCINOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 6/50
|
Neoplastic Lesions
|
Yes
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 9/50 38/50
|
Neoplastic Lesions
|
Yes
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 19/50 33/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 12/49 17/50 OR SQUAMOUS CELL CARCINOMA 0/50 7/47 6/50 COMBINED 0/50 18/49 19/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 12/50 20/50 OR SQUAMOUS CELL CARCINOMA 0/50 2/50 1/49 COMBINED 0/50 14/50 21/49
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 23/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 17/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 3/50 4/49; ADENOMATOUS POLYP 0/50 12/50 37/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 8/50 11/50; ADENOMATOUS POLYP 1/50 13/50 29/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 2/50 9/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 1/50 2/50 11/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULES 0/50 10/50 11/50 OR CARCINOMA 0/50 2/50 6/50 COMBINED 0/50 11/50 14/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULES 0/49 3/50 2/50 OR CARCINOMA 0/49 1/50 3/50 COMBINED 0/49 4/50 5/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 4/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 0/50 0/50 COMBINED 1/50 3/50 4/50
|
May Have Been Related
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 1/50 6/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 0/50 5/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 44/50 49/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 48/50 48/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 27/50 41/50 OR SQUAMOUS CELL CARCINOMA 0/50 15/50 27/50 COMBINED 0/50 39/50 49/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 40/50 33/50 OR SQUAMOUS CELL CARCINOMA 0/50 16/50 25/50 COMBINED 0/50 47/50 48/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 1/50 6/50; SEBACEOUS GLAND ADENOMA 0/50 3/50 2/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/50 9/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 3/50 11/50; SEBACEOUS GLAND ADENOMA 0/50 1/50 8/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA OR KERATOACANTHOMA 0/50 3/50 18/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 0/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 8/50 COMBINED 1/50 8/50 8/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA, OR KERATOACANTHOMA 0/50 20/50 31/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Vascular System (Spleen)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 0/50 3/50 OR HEMANGIOSARCOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 7/50 3/50 OR ADENOCARCINOMA 1/50 2/50 19/50 COMBINED 1/50 9/50 22/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 7/50 OR ADENOCARCINOMA 0/50 8/50 29/50 COMBINED 0/50 9/50 35/50
|
Neoplastic Lesions
|
Yes
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Female |
Gavage |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/49 3/50 1/49
|
Neoplastic Lesions
|
Yes
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Male |
Gavage |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 3/49 OR SQUAMOUS CELL CARCINOMA 0/50 4/50 1/49 COMBINED 0/50 6/50 4/49
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/50 40/47 36/43
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/48 3/47 8/44; SQUAMOUS CELL CARCINOMA 0/48 42/47 35/44
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 4/50 1/49 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 1/49 COMBINED 1/50 9/50 2/49
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/49 7/50 0/50; SQUAMOUS CELL CARCINOMA 0/49 7/50 0/50
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Female |
Gavage |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 3/49 6/41; CARCINOMA 0/50 11/49 28/41; SQUAMOUS CELL CARCINOMA 0/50 2/49 2/41
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Male |
Gavage |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/47 8/46 4/32; CARCINOMA 0/47 12/46 24/32; SQUAMOUS CELL CARCINOMA 0/47 3/46 0/32
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50 OR SQUAMOUS CELL CARCINOMA 0/50 2/50 1/50 COMBINED 0/50 2/50 5/50
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 2/50 COMBINED 0/50 5/50 4/50
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Mice |
B6C3F1 |
Male |
Gavage |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 1/48 3/47 16/44
|
Neoplastic Lesions
|